MeSH D004938 - esophageal neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D004938:
Esophageal neoplasms
D000077277:Esophageal squamous cell carcinoma
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Carboplatin | Carboplatin | 2005-09-21 | |||
| Cisplatin | Cisplatin | 2000-05-16 | ||||
| Novast Laboratories | Carboplatin | Carboplatin | 2017-04-26 | |||
| Mylan | Carboplatin | Carboplatin | 2007-04-24 | |||
| Cisplatin | Cisplatin | 2012-04-18 | ||||
| NATCO Pharma | Carboplatin | Carboplatin | 2012-05-29 | |||
| Cipla | Carboplatin | Carboplatin | 2006-01-27 | |||
| Sandoz | Carboplatin | Carboplatin | 2005-03-18 | |||
| Sun Pharmaceutical Industries | Carboplatin | Carboplatin | 2008-09-19 | |||
| Hospira | Carboplatin | Carboplatin | 2004-10-27 | |||
| Accord Healthcare | Carboplatin | Carboplatin | 2017-02-09 | |||
| Cisplatin | Cisplatin | 2015-08-18 | ||||
| Hikma Pharmaceuticals | Carboplatin | Carboplatin | 2004-10-14 | |||
| Cisplatin | Cisplatin | 2000-11-07 |
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
71%70/99
Phase 2
24%36/147
Phase 3
16%9/58
Approved: 3Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use